CDH17 and neoplasm: P. Xia et al. [152] conducted a study where they isolated EVs from human embryonic kidney (HEK-293) cells and employed genetic engineering techniques to incorporate nanobodies into EVs, aiming to enhance their tumor-targeting capabilities against CDH17-positive cancers.